Ankyra Therapeutics Appoints Sailaja Battula, PhD as Chief Scientific Officer
Ankyra Therapeutics, a clinical-stage biotech company in Cambridge, Mass., announced the appointment of Sailaja Battula, PhD, as its new Chief Scientific Officer (CSO).1
Dr. Battula has over a decade of experience in immuno-oncology, drug discovery, inflammation, and autoimmunity, with prior roles at Immuneering Corporation, Bicycle Therapeutics, Forma Therapeutics, and Applied Immunology.1
She holds a PhD in Pharmacology from New York Medical College and completed a postdoctoral fellowship at the University of California San Francisco.1
Howard Kaufman, MD, CEO of Ankyra, stated that Dr. Battula's expertise in advancing immuno-oncology programs will guide the company's pipeline.1
The announcement was made on December 16, 2025, as reported in BioSpace and other sources.14
Ankyra develops anchored drug conjugate technology, with lead candidate ANK-101 (tolododekin alfa), an IL-12 conjugate, in Phase 1 trials for solid tumors.13
Sources:
1. https://www.biospace.com/press-releases/ankyra-appoints-sailaja-battula-phd-as-chief-scientific-officer-cso
3. https://synapse.patsnap.com/organization/bee24c1210824bd7244ab3b3bce1cab0